Install
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES V
- 344articles · 30d
- 2+ hour agolatest article
- Aug 17, 2026earliest in window
- 92%with images
- 291avg words
- Economy, Business & Finance 196
- Health & Wellness 161
- Medical 159
- Business & Industrial 143
- Finance & Business 132
- Health 75
- Science & Technology 55
- Science & Nature 36
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Three Life-Saving Medical Technologies Named Finalists for the Second Annual Thomas J. Fogarty Innovation Prize
3+ day, 5+ hour ago (335+ words) Statistics cookies help us to understand how visitors interact with websites by collecting and reporting information anonymously. Marketing cookies allow us to display more relevant ads that are engaging for our users and thereby, they are more valuable for publishers…...
Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis
3+ day, 15+ hour ago (424+ words) BioSpace Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis - BYN-001 targets IL-25, an emerging upstream regulator of Type 2 inflammation implicated in atopic dermatitis, and leverages half-life extension technology - Bionyra is building…...
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
3+ day, 17+ hour ago (194+ words) BioSpace Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief…...
Encoded raises $275M series F for Dravet syndrome gene therapy
3+ day, 18+ hour ago (423+ words) Encoded Therapeutics has closed a $275 million series F round to help advance its investigational Dravet syndrome therapy into pivotal development. Much of the proceeds will go toward Encoded’s lead asset ETX101, according to a Wednesday release. The therapy is being tested…...
Ride Therapeutics Announces up to US$7.3 Million Investment from the Cystic Fibrosis Foundation to Advance Next-Generation Genetic Medicines
3+ day, 19+ hour ago (439+ words) BioSpace Ride Therapeutics Announces up to US$7.3 Million Investment from the Cystic Fibrosis Foundation to Advance Next-Generation Genetic Medicines - Investment will support Ride's Molecular Logistics™ platform with the goal of delivering genetic medicines to the lung for all people living…...
Trethera Congratulates Board Director Dr. Timothy R. Donahue on Appointment to Senior Leadership Roles at Weill Cornell Medicine and NewYork-Presbyterian
4+ day, 5+ hour ago (575+ words) BioSpace Trethera Congratulates Board Director Dr. Timothy R. Donahue on Appointment to Senior Leadership Roles at Weill Cornell Medicine and NewYork-Presbyterian LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases,…...
Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026
4+ day, 15+ hour ago (263+ words) Trialbee continues to bring fresh innovation to clinical trials with its Honey Platform™, demonstrating how AI is reshaping patient recruitment – and where it goes from here MALMO, Sweden & WILMINGTON, Del.--(BUSINESS WIRE)--Trialbee, the global patient recruitment leader reimagining clinical…...
Beren Therapeutics Launches ‘Test for NPC’ to Help Identify People with Niemann-Pick Disease, Type C Who Remain Undiagnosed
4+ day, 17+ hour ago (286+ words) According to the NPC Registry, it takes 2.5-4.3 years after a child’s first neurological symptom to diagnose them with I-NPC. Due to the progressive nature of the disease, early diagnosis is critical to enabling families and healthcare professionals to make earlier…...